Lupin Limited (LUPIN) — Financial Results | 12 February 2025(4 announcements)

Lupin Limited reported consolidated revenue of ₹118,884.5 crores for the nine-month period ending December 31, 2024, up sharply from ₹40,254.4 crores in the prior quarter, with net profit after tax reaching ₹2,071.0 crores. The Limited Review by B S R & Co. LLP confirms no modifications to financial statements under Ind AS 34, covering 17 subsidiaries deemed non-material. Revenue growth reflects strong performance across key therapeutic areas, though comprehensive income showed a minor loss in the quarter. The filing underscores regulatory compliance and digital verification via UDIN-linked signature.

Lupin Limited reported consolidated revenue of ₹11,888.45 crores for Q3 FY2024, up 69.9% YoY, with net profit surging 132.5% YoY to ₹2,071 crores. The unaudited results, approved on February 11, 2025, reflect strong performance across key subsidiaries and global operations, including gains from Lupin Inc. and YL Biologics. Limited review confirms compliance with SEBI and Ind AS 34 standards, with no material misstatements identified.

Lupin reported Q3 FY2025 revenue of ₹56,186 crores, up 10.6% YoY and 2.2% QoQ, with EBITDA rising 32.1% YoY to ₹14,096 crores and PAT up 38.8% YoY to ₹8,589 crores. Gross margin improved to 69.4% from 66.0% YoY, driven by margin expansion and stable employee costs at 17.5% of sales. Operating working capital stood at ₹70,700 crores, and net debt was ₹1,027 crores. The company highlighted strong U.S. growth, new product launches, and 6 FDA approvals, supporting its outlook for sustained momentum in upcoming quarters.

Lupin reported Q3 FY2025 revenue of ₹56,186 crores, up 10.6% YoY, with EBITDA rising 32.1% to ₹14,096 crores and PAT up 38.8% to ₹8,589 crores. Gross margin improved to 69.4% from 66.0%, while operating working capital reached ₹70,700 crores. The company highlighted strong US growth and sustained momentum across key markets.